Table 4.
Baseline Characteristics of Neurological Manifestations in the Included Studies. a
| Neurological Manifestations/Disorder | Study Type (no.) | Number of Patients Neurological/Total (%) | COVID-19 Severity Category No. (%) |
|---|---|---|---|
| Dizziness | Retrospective observational study (n = 3) | 58/488 (11.9%) | Nonsevere: 24 (41.4%) Severe: 34 (58.6%) |
| Headache | Retrospective observational study (n = 8) | 211/1784 (11.8%) | Nonsevere: 147 (72.4%)a Severe: 56 (27.6%) |
| Confusion/DCL | Retrospective observational study (n = 2) | 25/313 (8%) | Nonsevere: 3 (18.8%)a Severe: 13 (81.2%) |
| Taste impairment | Retrospective observational study (n = 1) | 12/214 (5.6%) | Nonsevere: 9 (75%) Severe: 3 (25%) |
| Smell impairment | Retrospective observational study (n = 1) | 11/214 (5.1%) | Nonsevere: 8 (72.7%) Severe: 3 (27.3%) |
| Cerebrovascular disease/stroke | Retrospective observational study (n = 2) | 19/435 (4.4%) | Nonsevere: 1 (5.3%) Severe: 18 (94.7%) |
| Nerve pains | Retrospective observational study (n = 1) | 5/214 (2.3%) | Nonsevere: 1 (20%) Severe: 4 (80%) |
| Vision impairment | Retrospective observational study (n = 1) | 3/214 (1.4%) | Nonsevere: 1 (33.3%) Severe: 2 (66.7%) |
| Ataxia | Retrospective observational study (n = 1) | 1/214 (0.5%) | Nonsevere: 0 Severe: 1 (100%) |
| Seizure | Retrospective observational study (n = 1) | 1/214 (0.5%) | Nonsevere: 0 Severe: 1 (100%) |
NB: COVID-19 severity either (1) nonsevere includes: mild, moderate symptoms, or non-ICU/ward patients or (2) severe includes: severe symptoms or ICU patients.
Abbreviations: DCL, disturbed conscious level; no., number.
a
Chen et al (2020) study not reported severity of COVID-19 according to neurological symptoms, so patients were excluded from analysis in severity column.